Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306831 | 0.86 | RAB9A (0.39) | ALDH1A1RAB9APOLBDPP4 | |
| SCHEMBL13667364 | 0.85 | AVPR2 (0.40) | ALDH1A1HMOX1TP53POLBAVPR2 | |
| SCHEMBL4310318 | 0.85 | AVPR2 (0.40) | ALDH1A1HMOX1TP53POLBAVPR2 | |
| SCHEMBL13667365 | 0.85 | AVPR2 (0.40) | ALDH1A1HMOX1TP53POLBAVPR2 | |
| SCHEMBL4304627 | 0.82 | HMOX1 (0.43) | HMOX1TP53 | |
| SCHEMBL4309086 | 0.80 | DPP4 (0.36) | ALDH1A1HMOX1RAB9APOLBIDO1 | |
| SCHEMBL4313709 | 0.78 | POLB (0.36) | POLBAVPR2AVPR1AGAAIDO1 | |
| SCHEMBL13667447 | 0.77 | MEN1 (0.37) | ALDH1A1HMOX1TP53POLB | |
| SCHEMBL13667446 | 0.77 | MEN1 (0.37) | ALDH1A1HMOX1TP53POLB | |
| SCHEMBL4313237 | 0.76 | MAPK1 (0.39) | ALDH1A1POLBAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | ALDH1A1 1039/4885HMOX1 1965/4885TP53 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.